Related Experiment Video
Updated: Jul 18, 2026
08:00
Colorimetric Assessment of Deiodinase 1 Activity in Human Liver Microsomes Using the Sandell-Kolthoff Reaction
Published on: April 10, 2026
Contraindication labelling changes in the United States and Germany.
Edeltraut Garbe1, Frank Andersohn
1Department of Clinical Pharmacology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. edeltraut.garbe@charite.de
European Journal of Clinical Pharmacology
|November 25, 2006
Summary
Drug contraindication labeling differs significantly between the US and Germany. A third of new US contraindications were not in German drug labels, with a median delay of 14 months.
Area of Science:
- Pharmacovigilance
- Regulatory Science
- Drug Safety
Background:
- Effective drug risk management relies on clear communication of benefits and risks via drug labeling.
- Contraindication labeling offers the most definitive safety guidance for healthcare professionals.
- International harmonization of drug safety information is crucial for patient protection.
Purpose of the Study:
- To compare the incorporation of new contraindications in US drug labeling into German Summary of Product Characteristics (SPC).
- To identify discrepancies and time lags in contraindication labeling between the US and Germany.
- To assess the extent of differences in drug safety information communicated to practitioners.
Main Methods:
- Comparative analysis of newly labeled US contraindications between January 2003 and May 2005.
- Assessment of their inclusion in German SPCs by October 2005.
- Classification of differences as none, slight (detail variation), or relevant (omission).
Main Results:
- Out of 66 new contraindications, 33.3% were not incorporated into German SPCs.
- No or slight differences were observed in 66.7% of cases.
- A median delay of 14 months existed for relevant differences, ranging from 5 to 31 months.
Conclusions:
- Significant discrepancies exist in contraindication labeling between the US and Germany.
- These differences pose potential risks to patient safety due to delayed or absent information.
- Further investigation into the reasons behind these labeling discrepancies is warranted.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:17Drug Nomenclature
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...